Physician profile
John Young Ko
NPI 1033841101
$1,766.66
in general payments reported to CMS, 2019-2025
18 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.64 · 2023: $60.73 · 2024: $332 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $529.81 | 2025 | |
| Novo Nordisk INC | $183.84 | 2022-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.17 | 2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $121.95 | 2024 | |
| Gilead Sciences, INC. | $121.83 | 2025 | Epclusa |
| Astrazeneca Pharmaceuticals LP | $115.35 | 2024 | Fasenra |
| Aimmune Therapeutics, INC. | $110.11 | 2025 | Zenpep |
| Janssen Biotech, INC. | $101.10 | 2025 | Tremfya |
| Boston Scientific Corporation | $87.68 | 2025 | General - Therapies |
| Madrigal Pharmaceuticals | $84.90 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $32.98 | 2024-2025 | Winrevair, Keytruda |
| Xeris Pharmaceuticals, INC. | $32.05 | 2023-2024 | Gvoke Hypopen |
| Amgen INC. | $27.25 | 2023 | Tezspire |
| Almatica Pharma LLC | $23.42 | 2024 | Teriparatide |
| Radius Health, INC. | $20.66 | 2024 | Tymlos |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $18.20 | 2023 | Afrezza |
| Alexion Pharmaceuticals, INC. | $17.44 | 2024 | Strensiq |
| Medtronic, INC. | $13.92 | 2025 | Manoscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.